Two Sigma Investments LP Sells 1,900 Shares of Inogen, Inc. (NASDAQ:INGN)

Two Sigma Investments LP cut its position in Inogen, Inc. (NASDAQ:INGN) by 6.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,549 shares of the medical technology company’s stock after selling 1,900 shares during the quarter. Two Sigma Investments LP owned about 0.12% of Inogen worth $253,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in INGN. Royce & Associates LP boosted its stake in Inogen by 499.7% in the 4th quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company’s stock valued at $2,854,000 after purchasing an additional 259,308 shares during the period. Prudential Financial Inc. boosted its stake in Inogen by 141.5% in the 4th quarter. Prudential Financial Inc. now owns 360,002 shares of the medical technology company’s stock valued at $3,301,000 after purchasing an additional 210,961 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in Inogen by 154.8% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 263,561 shares of the medical technology company’s stock valued at $2,417,000 after purchasing an additional 160,106 shares during the period. Dimensional Fund Advisors LP raised its holdings in Inogen by 25.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after acquiring an additional 123,208 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Inogen by 162.5% in the 4th quarter. Millennium Management LLC now owns 143,653 shares of the medical technology company’s stock valued at $1,317,000 after acquiring an additional 88,924 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors.

Inogen Stock Performance

Inogen stock opened at $6.45 on Thursday. Inogen, Inc. has a 52 week low of $5.70 and a 52 week high of $13.33. The stock has a market capitalization of $173.42 million, a P/E ratio of -2.87 and a beta of 1.64. The stock has a fifty day moving average of $6.69 and a 200-day moving average of $8.40.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.27. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. The company had revenue of $82.28 million during the quarter, compared to analysts’ expectations of $79.57 million. On average, research analysts forecast that Inogen, Inc. will post -1.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on INGN shares. Stifel Nicolaus dropped their price objective on Inogen from $10.00 to $7.00 and set a “hold” rating for the company in a report on Thursday, May 8th. Wall Street Zen cut Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC raised Inogen from a “hold” rating to a “moderate buy” rating and set a $12.00 price objective for the company in a report on Thursday, May 22nd.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.